The Most Expensive AI Mistake in Biotech Isn't a Hallucination, It's a Process Failure

AI failures in regulated biotech will stem not from model hallucinations but from treating AI as a standalone tool outside established governance frameworks, risking uncontrolled processes that regulators cannot audit. Life sciences must extend validation and change control to encompass the entire AI-assisted workflow, not just the model itself.

This Wire brief sits within Fusion42's coverage of Biotech and Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.